NEU neuren pharmaceuticals limited

Ann: 2024 results - A$166m comprehensive income for shareholders, page-43

  1. 2,535 Posts.
    lightbulb Created with Sketch. 691
    We know Gerry stated that there have been mulitple companies express interest in NNZ-2591. I would eat my hat if Acadia isn't one of those companies, particuarly given the comments relating to 'wanting to avoid a backended deal like we did with Daybue'.

    Either Australian investors are incredibly short sighted or Acadia is still angling for a scrip takeover or will partner up with a larger investment bank to give them the firepower to take out the company.

    Whilst I admit I am just speculating the performance disconnection after Neuren announced its second NNZ-2591 result is hard to ignore.

    The second result for Pit Hopkins showed our first result wasn't a fluke. At that time Acadia only commanded a 25%~ premium over Neuren in USD terms but just over 6 months later that premium is well over 200% depsite a further positive NNZ-2591 read out occuring in that time. Our performance has been dicatated by Daybue you say? Has it?

    A way to keep existing holders of Acadia happy would be to issue shares where the acquiring company has a larger valuation gap. It is a lot easier to stomach the dilution that way.


    https://hotcopper.com.au/data/attachments/6849/6849107-791a26cc3f86615af871f442f8454f2a.jpg

 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$12.54
Change
0.000(0.00%)
Mkt cap ! $1.559B
Open High Low Value Volume
$12.61 $12.68 $12.32 $7.219M 577.9K

Buyers (Bids)

No. Vol. Price($)
1 2968 $12.51
 

Sellers (Offers)

Price($) Vol. No.
$12.57 540 1
View Market Depth
Last trade - 16.16pm 25/06/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.